Late Breaking Poster Abstract Sessions

Barbosa, Meire de Oliveira; Santos, Alexandre Dos; Santos, Lázaro Antônio dos; Palma, Mariana; Ferreira, Fátima; Briza, Peter; Erler, Anja; Pomés, Anna; Arruda, L. Karla

doi:10.1111/j.1398-9995.2009.02078.x

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… a Frequency of mast cell (MC) mediator-related symptoms of 2% in pediatric mastocytosis and 14% in adult mastocytosis 83 b Frequency of MC mediator-related symptoms and anaphylaxis of 2% and 0.4% in adult mastocytosis, respectively 84 ; 4% of MC mediator-related symptoms and 0–2% of anaphylaxis in pediatric mastocytosis 84– 86 c Prophylactic anti-mediator therapy is recommended in all cases 87 d Infrequent, based on one case report (Javed Sheik, Beth Israel Hospital, Harvard Medical School, personal communication, September 2002) e Infrequent, based on case report 88 f Infrequent, based on case reports 89, 90 GI, gastrointestinal; IgE, immunoglobulin E; NSAID, non-steroidal anti-inflammatory drug. Adapted with permission from Ergon 91 .…”

Section: Clinical Features Of Patients With Primary Mast Cell Activatmentioning

confidence: 99%

See 1 more Smart Citation

Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes

et al. 2016

View full text Add to dashboard Cite

Clonal mast cell activation syndromes and indolent systemic mastocytosis without skin involvement are two emerging entities that sometimes might be clinically difficult to distinguish, and they involve a great challenge for the physician from both a diagnostic and a therapeutic point of view. Furthermore, final diagnosis of both entities requires a bone marrow study; it is recommended that this be done in reference centers. In this article, we address the current consensus and guidelines for the suspicion, diagnosis, classification, treatment, and management of these two entities.

show abstract